Alpha-Blocker Prescribing Trends for Ureteral Stones: A Single-Centre Study.

IF 2.7 Q2 UROLOGY & NEPHROLOGY Research and Reports in Urology Pub Date : 2022-08-29 eCollection Date: 2022-01-01 DOI:10.2147/RRU.S372208

Liang G Qu, Garson Chan, Johan Gani

{"title":"Alpha-Blocker Prescribing Trends for Ureteral Stones: A Single-Centre Study.","authors":"Liang G Qu, Garson Chan, Johan Gani","doi":"10.2147/RRU.S372208","DOIUrl":null,"url":null,"abstract":"Purpose: Recommendations for alpha-blockers have shifted in the conservative management of ureteral stones. It is unknown whether real-life practices regarding alpha-blocker prescriptions reflect updates in evidence. This study aimed to characterise alpha-blocker prescriptions for conservatively managed ureteral stones and relate this to recent literature.Methods: This was a retrospective audit, 01/01/2014 to 01/01/2019, of emergency acute renal colic presentations. Patients were included if they had a confirmed ureteral stone and were conservatively managed. The rates of alpha-blocker prescriptions were analysed using interrupted time-series analyses. May 2015 was selected as the cut-point to analyse before and after trend lines. Results were stratified by stone size and location. Tamsulosin and prazosin prescriptions were also compared.Results: This study included 2163 presentations: 70.4% were stones ≤5 mm and 61.4% were proximal stones. Altogether, 24.7% of presentations were prescribed alpha-blockers. There was a fall in alpha-blocker prescription rates from before to after May 2015, regardless of stone size or location (p < 0.001). Since May 2015, however, there was a monthly rate increase of 0.5% for patients with stones >5mm.Conclusion: This study demonstrated a significant shift in rates of alpha-blocker prescriptions, possibly related to the influence of updates in available high-quality evidence.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":" ","pages":"297-303"},"PeriodicalIF":2.7000,"publicationDate":"2022-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/bf/rru-14-297.PMC9439643.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Reports in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/RRU.S372208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Recommendations for alpha-blockers have shifted in the conservative management of ureteral stones. It is unknown whether real-life practices regarding alpha-blocker prescriptions reflect updates in evidence. This study aimed to characterise alpha-blocker prescriptions for conservatively managed ureteral stones and relate this to recent literature.

Methods: This was a retrospective audit, 01/01/2014 to 01/01/2019, of emergency acute renal colic presentations. Patients were included if they had a confirmed ureteral stone and were conservatively managed. The rates of alpha-blocker prescriptions were analysed using interrupted time-series analyses. May 2015 was selected as the cut-point to analyse before and after trend lines. Results were stratified by stone size and location. Tamsulosin and prazosin prescriptions were also compared.

Results: This study included 2163 presentations: 70.4% were stones ≤5 mm and 61.4% were proximal stones. Altogether, 24.7% of presentations were prescribed alpha-blockers. There was a fall in alpha-blocker prescription rates from before to after May 2015, regardless of stone size or location (p < 0.001). Since May 2015, however, there was a monthly rate increase of 0.5% for patients with stones >5mm.

Conclusion: This study demonstrated a significant shift in rates of alpha-blocker prescriptions, possibly related to the influence of updates in available high-quality evidence.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

输尿管结石的α受体阻滞剂处方趋势:单中心研究。

目的:在输尿管结石的保守治疗中，推荐使用α受体阻滞剂已经发生了变化。目前尚不清楚现实生活中关于α受体阻滞剂处方的实践是否反映了证据的更新。本研究旨在描述保守治疗输尿管结石的α受体阻滞剂处方，并将其与最近的文献联系起来。方法:回顾性分析2014年1月1日至2019年1月1日急诊急性肾绞痛病例。确诊输尿管结石并接受保守治疗的患者纳入研究。使用中断时间序列分析α -阻滞剂处方率。选取2015年5月作为切点，分析前后趋势线。结果按结石大小和位置分层。坦索罗辛与普拉唑嗪处方比较。结果:本研究共纳入2163例病例，70.4%为≤5 mm结石，61.4%为近端结石。总的来说，24.7%的患者服用了α受体阻滞剂。从2015年5月之前到之后，无论结石大小或位置如何，α受体阻滞剂处方率都有所下降(p < 0.001)。然而，自2015年5月以来，结石>5mm的患者每月的发生率增加了0.5%。结论:这项研究显示了α -受体阻滞剂处方率的显著变化，可能与现有高质量证据更新的影响有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Research and Reports in Urology UROLOGY & NEPHROLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Research and Reports in Urology is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease Investigation and treatment of urological disease Pharmacology of drugs used for the treatment of urological disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered.